Even if not deadly, up to 1 in 5 survivors can be left with serious and permanent sequelae.3-5
Read about risks of meningitisIt is estimated that only 33% of older adolescents have been vaccinated with a booster dose.6
Find booster ratesIMPORTANT SAFETY INFORMATION FOR MENACTRA VACCINE
Menactra vaccine is contraindicated in persons with a known hypersensitivity (eg, anaphylaxis) to any component of the vaccine.
Persons previously diagnosed with Guillain-Barré syndrome (GBS) may be at increased risk of GBS following receipt of Menactra vaccine. GBS has been reported in temporal relationship following administration of Menactra vaccine. The decision to give Menactra vaccine should be based on careful consideration of the potential benefits and risks.
Syncope (fainting) can occur in association with administration of injectable vaccines, including Menactra vaccine. Procedures should be in place to prevent falling injury and manage syncopal reactions.
The most common local and systemic adverse reactions to Menactra vaccine include pain, redness, and swelling at the injection site and appetite loss (all age groups); induration at the injection site and diarrhea (all age groups except infants); irritability and drowsiness (infants and children); abnormal crying, vomiting, and fever (infants); headache, fatigue, malaise, and arthralgia (adolescents and adults). Other adverse reactions may occur. Vaccination with Menactra vaccine may not protect all individuals.
INDICATION FOR MENACTRA VACCINE
Menactra vaccine is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Menactra vaccine is approved for use in individuals 9 months through 55 years of age. Menactra vaccine does not prevent N meningitidis serogroup B disease.
Before administering Menactra vaccine, please see accompanying full Prescribing Information.
- 1. Menactra vaccine [Prescribing Information]. Swiftwater, PA: Sanofi Pasteur Inc.; 2016. 2. World Health Organization. Media centre: meningococcal meningitis—fact sheet No.141. http://www.who.int/mediacentre/factsheets/fs141/en. Updated November 2015. Accessed March 16, 2017. 3. Hamborsky J, Kroger A, Wolfe S, eds. Meningococcal disease. In: Hamborsky J, Kroger A, Wolfe S, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 13th ed. Washington DC: Public Health Foundation; 2015:231-246. 4. Erickson L, De Wals P. Complications and sequelae of meningococcal disease in Quebec, Canada, 1990-1994. Clin Infect Dis.1998;26(5):1159-1164. 5. Borg J, Christie D, Coen PG, Booy R, Viner RM. Outcomes of meningococcal disease in adolescence: prospective, matched-cohort study. Pediatrics. 2009;123(3):e502-e509. 6. Centers for Disease Control and Prevention. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years—United States, 2015. MMWR. 2016;65(33):850-858.
